Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Head & Neck 4Genitourinary 3Gastrointestinal 3Dermatologic 3Thoracic 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 13Neoplasms 8Melanoma 6Neoplasm Metastasis 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Adenocarcinoma 2Vaccinia 1Uterine Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 12Carboplatin 6atezolizumab 5Trastuzumab 5aldesleukin 4Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4Cisplatin 4Bevacizumab 4spartalizumab 3fludarabine 3durvalumab 3Polymerase Chain Reaction 3Irinotecan 3Interleukin-2 3Gene Expression Profiling 3Blood Specimen Collection 3Biopsy 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2osimertinib 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × cemiplimab × Thoracic × Clear all
NCT06923761 2026-01-28

EMITT-1

Grey Wolf Therapeutics

Phase 1/2 Recruiting
300 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡